Valuation : Zai Lab Limited

Market Cap 271.01Cr 233.5Cr 221.1Cr 200.4Cr 375.96Cr 26TCr 377.87Cr 2.63TCr 1.01TCr 13TCr 1.02TCr 995.48Cr 42TCr P/E 2026 *
-10.9x
P/E 2027 * -10.9x
Enterprise Value 225.25Cr 194.07Cr 183.76Cr 166.56Cr 312.48Cr 22TCr 314.06Cr 2.18TCr 839.26Cr 11TCr 845.93Cr 827.37Cr 35TCr EV / Sales 2026 *
5.16x
EV / Sales 2027 * 4.22x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 week-7.08%
Current month-3.67%
1 month-7.08%
3 months+40.00%
6 months+26.51%
Current year+40.94%
1 week 20.8
Extreme 20.8
22.6
1 month 20.8
Extreme 20.8
23.6
3 years 12.8
Extreme 12.8
38.8
5 years 12.8
Extreme 12.8
116
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-7.08%-23.91%-14.63% 270.9Cr
-1.48%-5.59%+37.54%-6.24% 7.8TCr
-1.42%-4.24%-18.81%-37.78% 5.74TCr
+5.38%-1.09%+467.03%+36.08% 5.75TCr
-0.56%-2.21%-11.17%+25.38% 4.88TCr
+1.93%-2.37%-2.00%+149.45% 4.55TCr
+0.80%-1.67%+45.89%-16.13% 3.21TCr
-1.47%-4.17%+40.97%+88.59% 2.46TCr
-0.85%-8.64%-3.66%+144.26% 2.08TCr
-0.09%-3.61%+63.58%+97.66% 1.57TCr
Average +0.25%-3.87%+59.55%+46.66% 4.23TCr
Weighted average by Cap. +0.38%-3.71%+81.95%+35.53%

Financials

2026 *2027 *
Net sales 44Cr 38Cr 36Cr 32Cr 61Cr 4.17TCr 61Cr 422.91Cr 162.63Cr 2.12TCr 163.92Cr 160.32Cr 6.7TCr 55Cr 48Cr 45Cr 41Cr 77Cr 5.27TCr 77Cr 534.98Cr 205.72Cr 2.68TCr 207.36Cr 202.81Cr 8.48TCr
Net income -24Cr -21Cr -20Cr -18Cr -33Cr -2.3TCr -34Cr -233.19Cr -90Cr -1.17TCr -90Cr -88Cr -3.7TCr -21Cr -18Cr -17Cr -16Cr -29Cr -2.02TCr -29Cr -204.52Cr -79Cr -1.03TCr -79Cr -78Cr -3.24TCr
Net Debt -46Cr -39Cr -37Cr -34Cr -63Cr -4.37TCr -64Cr -443.44Cr -170.52Cr -2.22TCr -171.88Cr -168.11Cr -7.03TCr -38Cr -33Cr -31Cr -28Cr -53Cr -3.64TCr -53Cr -368.99Cr -141.89Cr -1.85TCr -143.02Cr -139.88Cr -5.85TCr
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
11/26/11 €21.00 0.00%
10/26/10 €21.00 -3.67%
09/26/09 €21.80 -1.80%
08/26/08 €22.20 -0.89%
07/26/07 €22.40 -0.88%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
24.14USD
Average target price
33.14USD
Spread / Average Target
+37.28%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!